Divaya Bhutani

High Impact

Researcher

Last publication 2025 Last refreshed 2026-04-18

faculty

25 h-index 183 pubs 2,670 cited

Biography and Research Information

OverviewAI-generated summary

Divaya Bhutani's research focuses on the treatment of hematologic malignancies, particularly multiple myeloma and immunoglobulin light-chain amyloidosis (AL amyloidosis). Her work investigates the efficacy and safety of novel therapeutic agents and treatment regimens in these conditions.

Recent publications by Bhutani examine the use of daratumumab-based treatments and venetoclax for AL amyloidosis, as well as the role of monoclonal antibody CAEL-101. She has also published on the outcomes of teclistamab in relapsed refractory multiple myeloma and systemic immunoglobulin light chain amyloidosis, and the evolving spectrum of infections associated with bispecific antibody therapy in multiple myeloma. Further research includes studies on pembrolizumab combined with dinaciclib for hematologic malignancies and front-line daratumumab-based therapy for AL amyloidosis.

Bhutani's scholarship metrics include an h-index of 25, 183 total publications, and 2,670 total citations. She is recognized as a highly cited researcher. Her key collaborators at the University of Arkansas for Medical Sciences include Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, and Samer Al Hadidi, with whom she has co-authored multiple publications.

Metrics

  • h-index: 25
  • Publications: 183
  • Citations: 2,670

Selected Publications

  • Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
    3 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

258 Collaborators 116 Institutions 16 Countries

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics